Most Read Articles
Stephen Padilla, 23 May 2019
A recent study has shown an association between regular use of glucosamine supplement to relieve osteoarthritis pain and lower risk of cardiovascular disease (CVD) events.
Stephen Padilla, 6 days ago
The inclusion of two proanthocyanidin (PA)-rich apples into normal diets improves cardiovascular disease (CVD) risk factors by reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and intercellular cell adhesion molecule-1 (ICAM-1), as well as increasing microvascular vasodilation, in individuals with mildly elevated serum cholesterol concentrations, a recent study has shown.
Roshini Claire Anthony, 21 Dec 2019

In acutely ill medical patients, asymptomatic proximal deep-vein thrombosis (ASxDVT), as assessed via compression ultrasonography, is associated with an elevated risk of all-cause mortality, according to a post hoc analysis of the MAGELLAN* trial presented at ASH 2019.

Tristan Manalac, 14 Dec 2019
Luspatercept promotes red blood cell (RBC) transfusion independence among low-risk myelodysplastic syndrome (MDS) patients, according to a longer-term analysis of the MEDALIST study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).

Moderate/severe tricuspid regurgitation predicts survival after PMVR

22 Oct 2019

Moderate or severe tricuspid regurgitation (TR) after percutaneous mitral valve repair (PMVR) is associated with worse clinical outcomes and long-term survival, a recent study has found.

Researchers performed a retrospective observational investigation of 213 consecutive PMVR patients, who were divided into two groups according to the degree of TR: none/mild (n=129; mean age, 75.3±8.9 years; 71.3 percent male) and moderate/severe (n=84; mean age, 75.8±8.9 years; 60.7 percent male). Those in the latter group had worse functional capacity after the procedure.

The overall survival rates at 1 and 2 years after PMVR were 79.3 percent (n=169) and 63.4 percent (n=135), respectively. These figures were significantly higher in the no/mild vs moderate/severe TR groups (1 year: 85.3 percent vs 70.2 percent; p=0.011; 2 years: 68.2 percent vs 56.0 percent; p=0.025). The median survival time was 1,458 days.

Fully adjusted proportional hazards models confirmed that postprocedural TR grade was a significant and independent predictor of long-term survival (hazard ratio [HR], 2.055, 95 percent CI, 1.317–3.206; p=0.002).

Other predictive factors included a severely impaired postprocedural left ventricular systolic function (HR, 3.145, 1.199–8.250; p=0.020) and chronic kidney disease, defined either as estimated glomerular filtration rate 30–60 (HR, 1.917, 1.109–3.314; p=0.02) or <30 mL/min (HR, 3.969, 1.981–7.951; p<0.001)

“TR should be taken into account when patients undergo PMVR, including right ventricular characteristics and pulmonary pressure,” said researchers. “A closer monitoring and follow-up in patients with residual moderate to severe TR seems reasonable.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 23 May 2019
A recent study has shown an association between regular use of glucosamine supplement to relieve osteoarthritis pain and lower risk of cardiovascular disease (CVD) events.
Stephen Padilla, 6 days ago
The inclusion of two proanthocyanidin (PA)-rich apples into normal diets improves cardiovascular disease (CVD) risk factors by reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and intercellular cell adhesion molecule-1 (ICAM-1), as well as increasing microvascular vasodilation, in individuals with mildly elevated serum cholesterol concentrations, a recent study has shown.
Roshini Claire Anthony, 21 Dec 2019

In acutely ill medical patients, asymptomatic proximal deep-vein thrombosis (ASxDVT), as assessed via compression ultrasonography, is associated with an elevated risk of all-cause mortality, according to a post hoc analysis of the MAGELLAN* trial presented at ASH 2019.

Tristan Manalac, 14 Dec 2019
Luspatercept promotes red blood cell (RBC) transfusion independence among low-risk myelodysplastic syndrome (MDS) patients, according to a longer-term analysis of the MEDALIST study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).